Abstract
Orally administered plant-based cancer vaccines combine recombinant antigen production, cell-wall-mediated bioencapsulation and mucosal delivery, offering a potentially scalable and non-invasive vaccination platform. However, these technological advantages do not necessarily translate into therapeutic antitumor immunity. Following oral administration, plant-made antigens must survive gastrointestinal transit, reach relevant antigen-presenting cells and undergo effective presentation, including MHC-I cross-presentation, while avoiding intestinal tolerance. These requirements are particularly challenging for self-derived tumor-associated antigens. This review critically examines plant-expression platforms, antigen and glycan engineering, gastrointestinal release, mucosal uptake, immune activation and translational requirements. The evidence is organized in a tiered framework distinguishing plant-contained cancer antigens administered orally from parenterally administered plant-made cancer antigens, plant-based oral vaccines targeting oncogenic or other infectious agents and expression-only studies. Direct evidence remains limited to small preclinical investigations. The only identified study reporting an in vivo tumor outcome provided proof of concept that oral administration of a plant-made cancer antigen delayed tumor outgrowth; however, it used a small prophylactic tumor-challenge design and did not establish an antigen-directed immune mechanism or demonstrate therapeutic efficacy against established disease. Further development will require standardized pharmaceutical formulations, quantitative potency assays, established-tumor models and evidence of cross-presentation, functional tumor-reactive T cells, tumor infiltration and survival benefit. Orally administered plant-based cancer vaccines could be investigated as booster or maintenance components of prespecified combination regimens, particularly in minimal residual disease, but this proposed role and their therapeutic efficacy remain unproven.